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Abstract OBJEC TIVES: Molecular changes observed in endometrium with respect to 
menstrual cycle changes seem to be crucial for the reproductive function. 
Accumulation of cytotoxic cells increases the exposure of endometrial cells to 
apoptosis. Protection against apoptosis may be reached by endometrial cells by 
self molecular regulation. Metallothionein was suggested to participate in this 
process. The aim of our study was to evaluate endometrial MT immunoreactivity 
with respect to the menstrual cycle phases.
MATERIALS AND METHODS: MT expression was assessed using immunohis-
tochemistry method in 47 endometrial tissue samples derived from randomly 
selected patients with respect to the menstrual cycle phases – proliferative and 
secretory with distinguishing early, mid and late subphases in each. 
RESULTS: MT expression changes were observed respectively to hormonal 
fluctuations with the highest level during mid secretory phase and its respective 
decrease during the early, late secretory and mid proliferative menstrual cycle 
phases. The lowest MT immunoreactivity level was disclosed during early prolif-
erative phase. 
CONCLUSION: Significant differences in MT expression observed in endometrium 
with respect to menstrual cycle changes might suggest MT participation in 
endometrial cells protection against apoptosis. 
Introduction
Molecular changes concerning endometrial 
and immune cells present in decidua observed 
respectively to menstrual cycle changes seem to 
be crucial for the reproductive function. During 
decidualization the number of immune cells grow 
and endometrium is ready for the ovum implanta-
tion (implantation window). Epithelial endome-
trial cells are surrounded then by a high number of 
mononuclear cells including NK, macrophages, T 
lymphocytes and other cells [9,17]. Accumulation 
of cytotoxic cells increases the exposure of endo-
metrial cells to apoptosis. The integrity of endo-
metrial tissue can be preserved owing to its ability 
to regulate the cytotoxic immune response. Many 
factors accumulated in endometrium at the time of 
implantation window possess immunomodulating 
activity such as: Galectin, VEGF, RCAS1 and other 
[5,14,15,16,24]. Protection against unwanted 
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apoptosis may be also reached by endometrial cell self 
molecular regulation. Metallothionein was suggested 
to participate in this process [6,7,26]. 
Metallothionein (MT) is a metal-binding low 
molecular weight protein with functional roles in cell 
growth, repair and differentiation [1,21]. It is also 
known that perinuclear MT location is important for 
protective function of MT against DNA damage and 
apoptosis induced by external stress stimuli [11,22]. 
According to this study it was suggested that MT over-
expression might protect the tumor cells from entering 
the apoptotic process and thereby to contribute to 
tumor expansion. The relation between MT expression 
and primary invasive breast cancer progression was 
observed [8]. MT seems to be a biomarker of tumor dif-
ferentiation and aggressiveness [3]. MT expression was 
increased in endometrial carcinoma cases compared 
with benign hyperplastic endometrial lesions [13]. 
The aim of our study was to evaluate MT immuno-
reactivity in normal endometrium with respect to the 
menstrual cycle phases – proliferative and secretory 
with distinguishing early, mid and late subphases in 
each. 
Materials and Methods
 Human subjects
Eutopic human endometrium tissues were obtained 
from non-menopausal fertile women, aged 25–45 years. 
These patients underwent hysterectomy because of 
benign gynecological indication (leiomyomas), laparo-
scopic or hysteroscopic diagnostic procedures. Patients’ 
agreement was obtained in all cases. The approval for 
the research program of the Jagiellonian University 
Ethical Committee was obtained prior to the study. No 
patient included in our study received any hormonal 
treatment. The surgical procedure was performed in 
Gynecology and Infertility Department of the Jagiel-
lonian University in Krakow, Poland. 450 women with 
the symptoms of benign gynecological lesion were 
referred to the Gynecology and Infertility Department 
between March 2004 and March 2005. Finally, 47 out 
of 450 women were randomly selected to our study. All 
tissue samples were verified by the standard histology 
using hematoxylin and eosin staining technique fol-
lowing formalin fixation. Tissue samples were classified 
according to the menstrual cycle phases, with division 
of the cycle into seven phases: early proliferative (7 
cases), mid proliferative (10 cases), late proliferative 
(4 cases), early secretory (5 cases), mid secretory (12 
cases), late secretory (5 cases) and menstrual bleeding 
(4 cases). 
Immunohistochemistry method
In all cases immunohistochemistry was performed 
applying Envision method using Dako Autostainer. 
For metallothionein immunostaining the monoclonal 
mouse antibody anti-metallothionein (Stressgen Bio-
reagents, Canada, dilution 1:40) was used, without any 
previous unmasking procedure, with 60-min-incuba-
tion at the room temperature. The positive control for 
this protein was a tissue taken from breast carcinoma. 
MT expression was evaluated in the entire slide (stro-
mal and epithelial endometrial cells), as follows: 
0  – lack of any expression, 
1+ – weak/strong expression in up to 10% of the cells, 
2+ –  weak expression in 11–50% of the cells or strong 
(also nuclear) expression in 11–30% of the cells, 
3+ – stronger expression than 2+. 
The used method was described in details in our previ-
ous reports [26].
Statistical analysis
The distribution of the data was analyzed using 
Shapiro-Wilk’s test. The results were compared with the 
use of Student’s t-test for normally distributed data and 
Mann-Whitney U test if non normal distribution was 
found. Significance of differences between the groups 
was set at p<0.05.
 Results
MT expression was evaluated in 47 endometrial 
tissue samples, from which 19% (9 cases) were MT 
expression negative. (Table 1)
The highest MT expression was observed in endo-
metrium in mid secretory menstrual cycle phase and 
was statistically significantly higher than in early, mid 
and late proliferative phases (respectively p=0.003, 
p<0.001, p<0.001). Significant differences in MT 
Table 1. Analysis of MT immunoreactivity in endometrial tissue samples with respect to menstrual cycle changes.
Variables
MT immunoreactivity
0 +1 +2 +3
Endometrium in early proliferative cycle phase (n=7) 28 (2) 72 (5) – –
Endometrium in mid proliferative cycle phase (n=10) – 40 (4) 60 (6) –
Endometrium in late proliferative cycle phase (n=4) 75 (3) – 25 (1) –
Endometrium in early secretory cycle phase (n=5) 20 (1) – 40 (2) 40 (2)
Endometrium in mid secretory cycle phase (n=12) – – 50 (6) 50 (6)
Endometrium in late secretory cycle phase (n=5) – 40 (2) 40 (2) 20 (1)
Menstrual bleeding (n=4) – 75 (3) 25 (1) –
665Neuroendocrinology Letters No.6 December Vol.26, 2005 Copyright © Neuroendocrinology Letters ISSN 0172–780X   www.nel.edu
Cycle dependent expression of endometrial metallothionein
expression were also observed between mid secretory 
endometrium and endometrium during menstruation 
(p=0.002). The level of MT immunoreactivity was 
higher in endometrium during mid secretory phase 
than in endometrium during early and late secretory 
cycle phases (p=0.17, p=0.58). MT expression in 
endometrium during the early and late secretory cycle 
phases was at the level comparable to the expression in 
endometrium during the mid proliferative phase. Sig-
nificant differences were identified in MT endometrial 
immunoreactivity level between the mid proliferative 
and early proliferative cycle phases (p=0.01). Similarly, 
significant differences in MT expression were found 
between mid proliferative and late proliferative men-
strual cycle phases (p=0.08). MT expression was signif-
icantly higher during the early and late secretory cycle 
phases than in early proliferative phase (p= 0.002, p= 
0.008). Additionally MT endometrial level was found 
to be higher in early and late secretory menstrual cycle 
phases than during the late proliferative one (p=0.001, 
p=0.006). The drop of MT expression during men-
struation was significantly lower only in comparison 
to the MT level in endometrium during mid secretory 
menstrual cycle phase.
Discussion
In the present study MT expression changes were 
observed respectively to hormonal fluctuations with 
the highest level during mid secretory phase and its 
respective decrease during the early, late secretory and 
mid proliferative menstrual cycle phases. The lowest 
MT immunoreactivity level was disclosed during early 
proliferative phase. 
Ioachin reported MT expression growth in normal 
endometrium during secretory cycle phase in com-
parison to proliferative one and an inverse correlation 
between MT and ER receptor [7]. MT gene is potentially 
down-regulated by estrogen receptor alpha, although 
MT expression in invasive ductal breast cancers was 
independent of ER status [20]. MT-I and MT-II genes 
expression seems to be controlled by progesterone, 
what was confirmed in vitro in endometrial cancer 
cell line (Ishikawa cells) [18]. Contrary to these find-
ings Ioachin observed an inverse correlation between 
MT values in normal endometrium and progesterone 
receptor content [7]. In our study MT immunoreactiv-
ity was significantly higher in secretory than in prolif-
erative cycle phase.
MT expression was recently demonstrated to be 
stimulated by INF-alpha in vitro [4]. In eutopic endo-
metrium INF-alpha concentration alters respectively 
to menstrual cycle phases and was at the highest level 
during mid secretory cycle phase [12]. INF-alpha is 
secreted by immune cells, concentration of which 
grows during secretory cycle phase and induces 
IL-2 and other cytokines secretion by immune cells, 
stimulating the cytotoxic response [2,19]. Receptors 
for INF-alpha are located in endometrial cells [23]. The 
increase of MT endometrial immunoreactivity during 
the implantation window seems to be secondary to the 
growing cytotoxic activity. It was suggested that MT 
expression might lead to induction of resistance against 
apoptosis [18]. Implantation window is the moment 
of IL-15 accumulation, which is crucial for dNK cells 
infiltration and activation [10]. MT expression results 
from an interaction between immune cells and endo-
metrial cells. In our previous report MT expression 
alterations were observed respectively to changes of 
number and activity of CD56 positive cells in eutopic 
endometrium, ovarian endometriosis and endometrial 
adenocarcinoma [25,26]. The protection of endometrial 
tissue function (ovum implantation, decidualization) 
requires the interaction between endometrial cells and 
immune cells, as the endometrial tissue integrity has to 
be preserved from the growing cytotoxic activity. 
In summary, significant differences in MT expres-
sion disclosed in endometrium with respect to men-
strual cycle changes might suggest MT participation in 
endometrial cells protection against apoptosis. 
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